FLT3 binds type I TKI

Stable Identifier
R-HSA-9695828
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

FLT3 can be bound and inhibited by class I tyrosine kinase inhibitors including sunitinib, lesaurtinib, crenolanib, gilteritinib and midostaurin, among others. Type I inhibitors bind in the ATP-binding site of the active conformation and prevent activation of the kinase (reviewed in Larrosa-Garcia and Baer, 2017; Lim et al, 2017; Klug et al, 2018).

Literature References
PubMed ID Title Journal Year
29964125 Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases

Klug, LR, Kent, JD, Heinrich, MC

Pharmacol. Ther. 2018
28576946 FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

Larrosa-Garcia, M, Baer, MR

Mol. Cancer Ther. 2017
28851395 Molecular targeting in acute myeloid leukemia

Lim, SH, Dubielecka, PM, Raghunathan, VM

J Transl Med 2017
Participants
Participant Of
hasEvent
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!